RCM
TERN

RA Capital Management’s Terns Pharmaceuticals TERN Stock Holding History

RA Capital Management’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,261,435
Closed -$3.13M – 94
2022
Q2 		$3.13M Buy
+1,261,435
New +$2.52M 0.08% 76

Other funds holding TERN

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

RA Capital Management's TERN Position: Q3 2022 in Review

RA Capital Management sold out of Terns Pharmaceuticals (TERN) in Q3 2022, closing a stake of 1,261,435 shares — an estimated $3.13M sold.

RA Capital Management first reported a position in TERN in Q2 2022 and held it in 1 quarter. The position peaked at $3.13M in Q2 2022. 45 funds tracked by Wall St. Rank hold TERN as of Q3 2022.

  • RA Capital Management reported no remaining Terns Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • RA Capital Management sold 1,261,435 Terns Pharmaceuticals shares in Q3 2022, an estimated $3.13M.
  • RA Capital Management first reported a position in Terns Pharmaceuticals in Q2 2022 and held it in 1 quarter.
  • RA Capital Management's Terns Pharmaceuticals position peaked at $3.13M in Q2 2022.
  • 45 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q3 2022.

Based on RA Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.